TWO2 Therapy Demonstrates Superior Long-Term Outcomes Compared to Other Advanced Wound Care Modalities: Real World Evidence Supported by Mechanistic and RCT Clinical Data

Background and Objectives: Chronic diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) remain a major source of morbidity, healthcare utilization, and limb loss, despite adherence to established standards of care protocols and the widespread availability of advanced wound technologies. Many advanced modalities only target isolated aspects of wound healing and fail to address the complex, interdependent pathophysiology of chronic wounds, particularly tissue hypoxia, edema, impaired microcirculation, and persistent inflammation. Cyclical Pressurized Topical Wound Oxygen (TWO2) therapy is a home‑based, multimodal intervention that combines humidified topical oxygen delivery with cyclical non‑contact compression to address these core drivers simultaneously. Materials and Methods: This review synthesizes mechanistic rationale and evidence from randomized controlled trials, long-term venous ulcer studies, and real-world comparative effectiveness analyses. Emphasis is placed on the large cohort study by Yellin et al., which directly compared TWO2 with other advanced modalities including negative pressure wound therapy (NPWT), skin substitutes, and growth factor therapies. Results: Across these studies, TWO2 therapy is consistently associated with improved healing durability, reduced recurrence, and substantial reductions in hospitalization and amputation rates compared with both standard care and advanced wound therapies. Conclusions: The convergence of randomized and real‑world evidence supports TWO2 therapy as a clinically meaningful and mechanism‑driven adjunctive treatment option for patients with chronic, high‑risk lower‑extremity wounds.